Header Logo

Connection

James Battiste to Recombinant Fusion Proteins

Back to Details
This is a "connection" page, showing publications James Battiste has written about Recombinant Fusion Proteins.
James Battiste
Connection Strength
0.040
Recombinant Fusion Proteins
  1. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.